Axxcess Wealth Management LLC Sells 2,667 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Axxcess Wealth Management LLC decreased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 17.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,651 shares of the company’s stock after selling 2,667 shares during the period. Axxcess Wealth Management LLC’s holdings in 10x Genomics were worth $182,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Signaturefd LLC raised its holdings in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after acquiring an additional 1,452 shares during the last quarter. Blue Trust Inc. raised its holdings in 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock worth $44,000 after acquiring an additional 1,299 shares during the last quarter. Sound Income Strategies LLC raised its holdings in 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after acquiring an additional 1,330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in 10x Genomics in the 4th quarter worth approximately $52,000. Finally, First Horizon Advisors Inc. raised its holdings in 10x Genomics by 53.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after acquiring an additional 1,012 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Price Performance

Shares of TXG stock opened at $10.39 on Friday. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -6.84 and a beta of 1.93. The firm has a fifty day moving average price of $12.68 and a 200-day moving average price of $15.53. 10x Genomics, Inc. has a 1 year low of $9.27 and a 1 year high of $38.49.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities research analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Insider Buying and Selling

In other news, insider Benjamin J. Hindson sold 4,573 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the sale, the insider now directly owns 335,324 shares in the company, valued at approximately $3,712,036.68. This represents a 1.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the sale, the chief executive officer now directly owns 879,482 shares in the company, valued at $9,735,865.74. This trade represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TXG has been the subject of a number of recent analyst reports. Leerink Partnrs lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Friday, March 7th. Stifel Nicolaus decreased their target price on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Morgan Stanley decreased their target price on shares of 10x Genomics from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, JPMorgan Chase & Co. decreased their target price on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $20.21.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.